Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence

被引:9
|
作者
Pereira, Antonio Dias [1 ,2 ]
Chaves, Paula [2 ,3 ]
机构
[1] Inst Portugues Oncol Francisco Gentil, Dept Gastroenterol, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal
[2] Univ Beira Interior, Fac Ciencias Saude, Covilha, Portugal
[3] Inst Portugues Oncol Francisco Gentil, Dept Pathol, Lisbon, Portugal
关键词
Adenocarcinoma; Barrett's esophagus; cancer risk; dysplasia; segment length; surveillance; POPULATION-BASED COHORT; MALIGNANT PROGRESSION; CANCER INCIDENCE; MORTALITY; METAANALYSIS; MANAGEMENT; SURVEILLANCE; ASSOCIATION; GUIDELINES; EXPERIENCE;
D O I
10.1177/2050640615612409
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The risk of esophageal adenocarcinoma (EAC) in non-dysplastic Barrett's esophagus (NDBE) is considered to be approximately 0.3% per year or even lower, according to population-based studies. Data from countries with low EAC incidence are scarce. Our principal aim was to determine the incidence of high-grade dysplasia (HGD) and EAC in NDBE. Our secondary aims were to identify the predictors of progression and to calculate the incidence of HGD/EAC, by using the calculation method for surveillance time in population-based studies. Materials and methods: A cohort of NDBE patients was prospectively followed up. Cases of HGD and EAC (study end points) diagnosed during the first year of follow-up were considered as prevalent. Only cases with an endoscopic surveillance time > 1 year were included in our analysis. Results: We enrolled 331 patients (251 men) in the surveillance program. Their median age was 59 years (interquartile range (IQR): 47-67 years). Their median NDBE length was 3 cm (IQR: 2-4 cm). Of these patients, 80 died during the follow-up (one from EAC) and two were lost to follow-up. After 2284 patient-years of endoscopic follow-up (median surveillance time, 5 years (IQR: 2-10 years)), we found that five cases of HGD and two cases of EAC were diagnosed. The incidence of HGD/EAC was 3.1 cases per 1000 patient-years (95% CI: 1.3-6.0) and that of EAC was 0.9 (95% CI: 0.2-2.9). The incidence of HGD/EAC in short segments (<= 3 cm) was 0.7 cases per 1000 patient-years (95% CI: 0.3-3.4). The sole variable that we found associated with progression was NDBE length. If the total surveillance time was considered (3537 patient-years), the incidence of HGD and EAC was only slight lower. Conclusions: The incidence of HGD and EAC was very low in NDBE. Therefore, current surveillance guidelines must be reassessed, at least for short-segment BE.
引用
收藏
页码:343 / 352
页数:10
相关论文
共 50 条
  • [21] Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low
    Kruijshaar, Michelle E.
    Siersema, Peter D.
    Janssens, A. Cecile J. W.
    Kerkhof, Marjon
    Steyerberg, Ewout W.
    Essink-Bot, Marie-Louise
    GASTROINTESTINAL ENDOSCOPY, 2007, 65 (01) : 26 - 30
  • [22] Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus
    Kariyawasam, Viraj C.
    Bourke, Michael J.
    Hourigan, Luke F.
    Lim, Gary
    Moss, Alan
    Williams, Stephen J.
    Fanning, Scott B.
    Chung, Adrian M.
    Byth, Karen
    GASTROINTESTINAL ENDOSCOPY, 2012, 75 (05) : 938 - 944
  • [23] Risk Factors for Progression of Low-Grade Dysplasia in Patients With Barrett's Esophagus
    Wani, Sachin
    Falk, Gary W.
    Post, Jane
    Yerian, Lisa
    Hall, Matthew
    Wang, Amy
    Gupta, Neil
    Gaddam, Srinivas
    Singh, Mandeep
    Singh, Vikas
    Chuang, Keng-Yu
    Boolchand, Vikram
    Gavini, Hemanth
    Kuczynski, John
    Sud, Priti
    Bansal, Ajay
    Rastogi, Amit
    Mathur, Sharad C.
    Young, Patrick
    Cash, Brooks
    Goldblum, John
    Lieberman, David A.
    Sampliner, Richard E.
    Sharma, Prateek
    GASTROENTEROLOGY, 2011, 141 (04) : 1179 - U590
  • [24] Low risk of esophageal adenocarcinoma among patients with ultrashort-segment Barrett's esophagus in Japan
    Fukuda, Sho
    Watanabe, Kenta
    Yoshida, Tatsuki
    Takahashi, So
    Fujimori, Shusei
    Horikawa, Yohei
    Komatsu, Taiga
    Shirane, Kenji
    Shimodaira, Yosuke
    Matsuhashi, Tamotsu
    Iijima, Katsunori
    DIGESTIVE ENDOSCOPY, 2022, 34 (04) : 757 - 765
  • [25] Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus
    Thota, Prashanthi N.
    Kistangari, Gaurav
    Singh, Prabhdeep
    Cummings, Linda
    Hajifathalian, Kaveh
    Lopez, Rocio
    Sanaka, Madhusudhan R.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (01) : 247 - 254
  • [26] Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis
    Singh, Siddharth
    Manickam, Palaniappan
    Amin, Anita V.
    Samala, Niharika
    Schouten, Leo J.
    Iyer, Prasad G.
    Desai, Tusar K.
    GASTROINTESTINAL ENDOSCOPY, 2014, 79 (06) : 897 - U248
  • [27] Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy
    Thota, Prashanthi N.
    Vennalaganti, Prashanth
    Vennelaganti, Sreekar
    Young, Patrick
    Gaddam, Srinivas
    Gupta, Neil
    Lieberman, David
    Sampliner, Richard
    Falk, Gary W.
    Mathur, Sharad
    Kennedy, Kevin
    Cash, Brooks D.
    Moawad, Fouad
    Bansal, Ajay
    Spaander, Manon C.
    Bruno, Marco J.
    Vargo, John
    Sharma, Prateek
    GASTROENTEROLOGY, 2017, 152 (05) : 987 - 992
  • [28] Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study
    Campos, Vinicius J.
    Mazzini, Guilherme S.
    Juchem, Jose F.
    Gurski, Richard R.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (01) : 8 - 18
  • [29] Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists
    Moole, Harsha
    Patel, Jaymon
    Ahmed, Zohair
    Duvvuri, Abhiram
    Vennelaganti, Sreekar
    Moole, Vishnu
    Dharmapuri, Sowmya
    Boddireddy, Raghuveer
    Yedama, Pratyusha
    Bondalapati, Naveen
    Uppu, Achuta
    Vennelaganti, Prashanth
    Puli, Srinivas
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (39) : 8831 - 8843
  • [30] Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma
    Goodarzi, Mahmoud
    Correa, Arlene M.
    Ajani, Jaffer A.
    Swisher, Stephen G.
    Hofstetter, Wayne L.
    Guha, Sushovan
    Deavers, Michael T.
    Rashid, Asif
    Maru, Dipen M.
    MODERN PATHOLOGY, 2009, 22 (12) : 1612 - 1621